Regenics AS: A Rising Star in Wound Care Innovation
May 21, 2025, 6:49 pm
In the world of biotechnology, few companies shine as brightly as Regenics AS. Based in Oslo, this Norwegian firm is making waves in the wound care sector. With recent developments, including a significant investment and a new CEO, Regenics is poised for growth. Their flagship product, Collex®, is at the heart of this transformation.
Regenics AS recently completed the second tranche of a private placement, raising NOK 33.2 million. This funding comes from Nordic Blue esf., an Icelandic venture capital fund with a keen interest in Blue Tech. The investment is a vote of confidence in Regenics and its innovative approach to wound care. Nordic Blue now holds 38.1% of Regenics’ shares, solidifying its role as a key player in the company’s future.
Collex® is not just another wound dressing. It’s a hydrogel designed to heal partial thickness burns and chronic wounds, including diabetic ulcers. The ingredients are all marine-based, sourced from the pristine Norwegian coast. One standout component is HTX™, derived from unfertilized salmon roe. This unique formulation aims to redefine wound treatment standards.
The timing of this investment is crucial. Regenics is in the late pre-clinical stage of Collex®, with promising results in wound healing rates. The company’s commitment to innovation is evident. They are not just developing products; they are crafting solutions for unmet medical needs in a multi-billion dollar market.
The leadership at Regenics is also evolving. Jostein Grip has been appointed as the new CEO, effective August 1, 2025. Grip brings a wealth of experience in wound healing product development. His PhD thesis focused on novel wound dressings, making him a perfect fit for Regenics. He previously served as CTO at Oxy Solutions, where he honed his skills in the industry.
Karin Gilljam, who has been the interim CEO, will transition back to her role as Chief Scientific Officer. Her expertise will continue to guide the company as it navigates this critical phase. The board of Regenics believes that Grip’s leadership will be instrumental in advancing Collex® and other product candidates.
The wound care market is vast and competitive. Companies are racing to develop effective treatments for chronic wounds, burns, and other injuries. Regenics stands out with its focus on marine biotechnology. This niche not only sets them apart but also aligns with global trends toward sustainable and natural products.
Investors are taking notice. The backing from Nordic Blue is significant. Their confidence in Regenics reflects a broader trend in the investment community. There is a growing recognition of the potential in marine-based innovations. As the world seeks sustainable solutions, companies like Regenics are well-positioned to lead the charge.
Regenics is not just about products; it’s about impact. The company aims to improve the quality of life for patients suffering from chronic wounds. By focusing on effective and sustainable solutions, they are addressing a critical healthcare challenge. The potential for Collex® to change the landscape of wound care is immense.
As Regenics moves forward, the combination of strong leadership, innovative products, and strategic investments will be key. The company is on a trajectory toward success. With Grip at the helm and Nordic Blue’s support, the future looks bright.
The journey of Regenics AS is a testament to the power of innovation in biotechnology. They are not merely participating in the market; they are shaping it. As they continue to develop Collex® and expand their product pipeline, the industry will be watching closely.
In conclusion, Regenics AS is a beacon of hope in the wound care sector. Their commitment to innovation, sustainability, and patient care sets them apart. With the right leadership and strategic partnerships, they are poised to make a significant impact. The world of wound care is evolving, and Regenics is leading the way. The next chapter in their story promises to be exciting, filled with potential and progress.
Regenics AS recently completed the second tranche of a private placement, raising NOK 33.2 million. This funding comes from Nordic Blue esf., an Icelandic venture capital fund with a keen interest in Blue Tech. The investment is a vote of confidence in Regenics and its innovative approach to wound care. Nordic Blue now holds 38.1% of Regenics’ shares, solidifying its role as a key player in the company’s future.
Collex® is not just another wound dressing. It’s a hydrogel designed to heal partial thickness burns and chronic wounds, including diabetic ulcers. The ingredients are all marine-based, sourced from the pristine Norwegian coast. One standout component is HTX™, derived from unfertilized salmon roe. This unique formulation aims to redefine wound treatment standards.
The timing of this investment is crucial. Regenics is in the late pre-clinical stage of Collex®, with promising results in wound healing rates. The company’s commitment to innovation is evident. They are not just developing products; they are crafting solutions for unmet medical needs in a multi-billion dollar market.
The leadership at Regenics is also evolving. Jostein Grip has been appointed as the new CEO, effective August 1, 2025. Grip brings a wealth of experience in wound healing product development. His PhD thesis focused on novel wound dressings, making him a perfect fit for Regenics. He previously served as CTO at Oxy Solutions, where he honed his skills in the industry.
Karin Gilljam, who has been the interim CEO, will transition back to her role as Chief Scientific Officer. Her expertise will continue to guide the company as it navigates this critical phase. The board of Regenics believes that Grip’s leadership will be instrumental in advancing Collex® and other product candidates.
The wound care market is vast and competitive. Companies are racing to develop effective treatments for chronic wounds, burns, and other injuries. Regenics stands out with its focus on marine biotechnology. This niche not only sets them apart but also aligns with global trends toward sustainable and natural products.
Investors are taking notice. The backing from Nordic Blue is significant. Their confidence in Regenics reflects a broader trend in the investment community. There is a growing recognition of the potential in marine-based innovations. As the world seeks sustainable solutions, companies like Regenics are well-positioned to lead the charge.
Regenics is not just about products; it’s about impact. The company aims to improve the quality of life for patients suffering from chronic wounds. By focusing on effective and sustainable solutions, they are addressing a critical healthcare challenge. The potential for Collex® to change the landscape of wound care is immense.
As Regenics moves forward, the combination of strong leadership, innovative products, and strategic investments will be key. The company is on a trajectory toward success. With Grip at the helm and Nordic Blue’s support, the future looks bright.
The journey of Regenics AS is a testament to the power of innovation in biotechnology. They are not merely participating in the market; they are shaping it. As they continue to develop Collex® and expand their product pipeline, the industry will be watching closely.
In conclusion, Regenics AS is a beacon of hope in the wound care sector. Their commitment to innovation, sustainability, and patient care sets them apart. With the right leadership and strategic partnerships, they are poised to make a significant impact. The world of wound care is evolving, and Regenics is leading the way. The next chapter in their story promises to be exciting, filled with potential and progress.